Update on the Pharmacological Treatment of Primary Biliary Cholangitis

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Aug 26

PMID 36009580

Authors

Annarosa Floreani

Daniela Gabbia

Sara De Martin

Affiliations

Soon will be listed here.

Abstract

Ursodeoxycholic acid (UDCA) is the first-line therapy used for the treatment of PBC. In recent years, new pharmacological agents have been proposed for PBC therapy to cure UDCA-non-responders. Obeticholic acid (OCA) is registered in many countries for PBC, and fibrates also seem to be effective in ameliorating biochemistry alteration and symptoms typical of PBC. Moreover, a variety of new agents, acting with different mechanisms of action, are under clinical evaluation for PBC treatment, including PPAR agonists, anti-NOX agents, immunomodulators, and mesenchymal stem cell transplantation. Since an insufficient amount of data is currently available about the effect of these novel approaches on robust clinical endpoints, such as transplant-free survival, their clinical approval needs to be supported by the consistent improvement of these parameters. The intensive research in this field will hopefully lead to a novel treatment landscape for PBC in the near future, with innovative therapies based on the combination of multiple agents acting on different pathogenetic mechanisms.

Citing Articles

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.

Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E Cells. 2024; 13(18.

PMID: 39329760 PMC: 11429758. DOI: 10.3390/cells13181580.

Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?.

Luo X, Lu L J Clin Transl Hepatol. 2024; 12(6):581-588.

PMID: 38974958 PMC: 11224908. DOI: 10.14218/JCTH.2023.00519.

Current Therapies for Cholestatic Diseases.

Mendez-Sanchez N, Coronel-Castillo C, Ordonez-Vazquez A Biomedicines. 2023; 11(6).

PMID: 37371808 PMC: 10296345. DOI: 10.3390/biomedicines11061713.

Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases.

Wang J Biomedicines. 2023; 11(4).

PMID: 37189758 PMC: 10135662. DOI: 10.3390/biomedicines11041140.

References

Tanaka H, Yang G, Iwakoshi N, Knechtle S, Kawata K, Tsuneyama K . Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clin Exp Immunol. 2013; 174(3):364-71. PMC: 3826303. DOI: 10.1111/cei.12193. View

Wang L, Li J, Liu H, Li Y, Fu J, Sun Y . Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 2013; 28 Suppl 1:85-92. DOI: 10.1111/jgh.12029. View

Zhang H, Yang J, Zhu R, Zheng Y, Zhou Y, Dai W . Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis. Drug Des Devel Ther. 2015; 9:567-74. PMC: 4304592. DOI: 10.2147/DDDT.S74515. View

Mayo M, Wigg A, Leggett B, Arnold H, Thompson A, Weltman M . NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Hepatol Commun. 2018; 2(9):1037-1050. PMC: 6128239. DOI: 10.1002/hep4.1209. View

Chuang Y, Lian Z, Cheng C, Lan R, Yang G, Moritoki Y . Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun. 2005; 25(2):126-32. DOI: 10.1016/j.jaut.2005.08.009. View

Gabbia D, Dalla Pozza A, Albertoni L, Lazzari R, Zigiotto G, Carrara M . Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis. World J Gastroenterol. 2017; 23(42):7519-7530. PMC: 5698245. DOI: 10.3748/wjg.v23.i42.7519. View

Gulamhusein A, Hirschfield G . Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2019; 17(2):93-110. DOI: 10.1038/s41575-019-0226-7. View

Webb G, Hirschfield G . Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun. 2015; 66:25-39. DOI: 10.1016/j.jaut.2015.08.016. View

Bowlus C, Yang G, Liu C, Johnson C, Dhaliwal S, Frank D . Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. J Autoimmun. 2019; 101:26-34. DOI: 10.1016/j.jaut.2019.04.005. View

10.

DAmato D, De Vincentis A, Malinverno F, Vigano M, Alvaro D, Pompili M . Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep. 2021; 3(2):100248. PMC: 7930359. DOI: 10.1016/j.jhepr.2021.100248. View

11.

Tsuda M, Moritoki Y, Lian Z, Zhang W, Yoshida K, Wakabayashi K . Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2011; 55(2):512-21. DOI: 10.1002/hep.24748. View

12.

Gochanour E, Kowdley K . Investigational drugs in early phase development for primary biliary cholangitis. Expert Opin Investig Drugs. 2020; 30(2):131-141. DOI: 10.1080/13543784.2021.1857364. View

13.

Mayo M, Pockros P, Jones D, Bowlus C, Levy C, Patanwala I . A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatol Commun. 2019; 3(3):365-381. PMC: 6396374. DOI: 10.1002/hep4.1305. View

14.

Mayo M . Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?. Hepatology. 2022; 76(2):518-531. DOI: 10.1002/hep.32405. View

15.

Cortez-Pinto H, Liberal R, Lopes S, Machado M, Carvalho J, Dias T . Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. United European Gastroenterol J. 2021; 9(6):699-706. PMC: 8280809. DOI: 10.1002/ueg2.12095. View

16.

Murillo Perez C, Harms M, Lindor K, van Buuren H, Hirschfield G, Corpechot C . Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol. 2020; 115(7):1066-1074. DOI: 10.14309/ajg.0000000000000557. View

17.

Gerussi A, Luca M, Cristoferi L, Ronca V, Mancuso C, Milani C . New Therapeutic Targets in Autoimmune Cholangiopathies. Front Med (Lausanne). 2020; 7:117. PMC: 7154090. DOI: 10.3389/fmed.2020.00117. View

18.

Juran B, Lazaridis K . Environmental factors in primary biliary cirrhosis. Semin Liver Dis. 2014; 34(3):265-72. PMC: 4232304. DOI: 10.1055/s-0034-1383726. View

19.

Corpechot C, Chazouilleres O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P . A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med. 2018; 378(23):2171-2181. DOI: 10.1056/NEJMoa1714519. View

20.

Gordon S, Trudeau S, Regev A, Uhas J, Chakladar S, Pinto-Correia A . Baricitinib and primary biliary cholangitis. J Transl Autoimmun. 2021; 4:100107. PMC: 8240017. DOI: 10.1016/j.jtauto.2021.100107. View